Findings
========

Nuclear factor-κB (NF-κB) transcription factors initiate transcription of genes essential for mounting an adequate immune response \[[@B1]\]. Ubiquitously expressed NF-κB heterodimers of Rel family proteins are normally sequestered in the cytosol of the cells by Inhibitors of NF-κB (IκBs) proteins \[[@B2]\]. In lymphocytes, the ligation of antigen receptors assembles the so-called CBM complex that consists of the scaffold CARMA1 and the heterodimer BCL10/MALT1 \[[@B3]\]. The CBM microenvironment drives oligomerized BCL10 and MALT1 to undergo K63-linked non-degradative ubiquitinylation \[[@B4]-[@B7]\]. This authorizes the recruitment and activation of the IκB kinase (IKK) complex that comprises two catalytic subunits (IKKα and IKKβ) and a regulatory subunit (NEMO, also called IKKγ) \[[@B8]\]. IKK phosphorylation of IκBs precipitates their K48-linked ubiquitinylation and proteasomal elimination, and thereby allows NF-κB to translocate to the nucleus where it binds DNA and initiates transcription \[[@B8]\]. NF-κB-dependent neosynthesis of IκBs subsequently drives NF-κB to shuttle back to the cytosol \[[@B1]\]. Although reversible ubiquitinylation processes are central for T-cell receptor-(TCR)-mediated NF-κB activation, the deubiquitinylases (DUBs) in charge of trimming these poly-ubiquitin chains to ensure optimal signaling, as well as to reset the system to basal levels remain poorly defined \[[@B9]\]. Thus far, two DUBs, namely cylindromatosis (CYLD) and A20 (also known as TNFAIP3), were demonstrated to negatively regulate antigen receptor signaling \[[@B9],[@B10]\]. Herein, we provide evidence that Ubiquitin-Specific Protease 34 (USP34) also contributes to the fine-tuning of NF-κB upon TCR engagement.

To identify additional negative regulators of TCR-mediated NF-κB activation, we conducted a siRNA library screen against 98 DUBs through a gene reporter luciferase assay in Jurkat T cells stimulated with either anti-CD3 and anti-CD28 antibodies or PMA plus ionomycin to mimic TCR engagement (Figure [1](#F1){ref-type="fig"}A and Additional files [1](#S1){ref-type="supplementary-material"} and [2](#S2){ref-type="supplementary-material"}). As expected, CYLD silencing led to an enhanced NF-κB activity upon TCR stimulation (Figure [1](#F1){ref-type="fig"}A). Furthermore, this screening also uncovered siRNA sequences specific for USP34 that potentiated NF-κB activation with a similar magnitude to CYLD siRNA (Figure [1](#F1){ref-type="fig"}A). USP34 encompasses a 404 kDa protein with a central catalytic domain \[[@B11]\]. However, little is known about this DUB, albeit it was previously linked to the Wnt developmental signaling pathway \[[@B12]\]. Subcellular fractionation experiments showed that USP34 was essentially distributed in the cytosol of cells regardless of TCR stimulation, and was notably absent from the nucleus and organelles (Figure [1](#F1){ref-type="fig"}B and Additional file [3](#S3){ref-type="supplementary-material"}A). We next verified by immunoblot that CYLD and USP34 endogenous levels were efficiently decreased by their respective siRNA sequences (Figure [1](#F1){ref-type="fig"}C). Of note, an additional siRNA duplex specific for USP34 was also included to reinforce our initial findings (named sequence 3). Consistent with the primary screening, NF-κB reporter activity was similarly boosted upon TCR stimulation in USP34- and CYLD-silenced Jurkat when compared to control non-targeting siRNA transfected cells (Figure [1](#F1){ref-type="fig"}D and E). As a consequence, the levels of the NF-κB targets NFKBIA (IκBα), interleukin-2 (IL-2) and TNFα, as measured by RT-PCR were increased in USP34-knocked down cells (Figure [1](#F1){ref-type="fig"}F). Accordingly, downstream IL-2 secretion was enhanced in supernatants of USP34-silenced cells (Figure [1](#F1){ref-type="fig"}G). Finally, ectopic expression of a plasmid encoding for the catalytic domain of USP34 (USP34-CD \[[@B13]\]) markedly dampened TCR-mediated NF-κB activity (Figure [1](#F1){ref-type="fig"}H). Because USP34-CD is a large segment (383 amino acids), it is possible that in addition to the catalytic domain, it also comprises a domain required for the binding to its partners to regulate NF-κB in lymphocytes. Collectively, our data suggest that USP34 is a cytosolic protein, which functions as a negative regulator of NF-κB upon TCR engagement.

![**Identification of USP34 as a negative regulator of TCR-mediated NF-κB activation. (A**) NF-κB reporter luciferase assay screen of a siRNA library targeting 98 DUBs (2 siRNA/target) in Jurkat T lymphocytes stimulated with 20 ng.ml^-1^ PMA plus 300 ng.ml^-1^ ionomycin (P/I, top panel), or with 0.5 μg.ml^-1^ anti-CD3 and anti-CD28 (bottom panel). Fold activation compared to non-targeting (n.t.) siRNA-treated cells is shown. Green and red histograms indicate siRNA against USP34 and CYLD, respectively. (**B**) Nuclear (Nucl.) and cytosolic (Cyt.) fractions from Jurkat T cells stimulated with P/I as in (**A**) for 0 and 15 min were analyzed by immunoblot. PARP and tubulin served as loading and purity controls for nucleus and cytosol, respectively. Molecular weight markers (*M.W.*) are indicated. (**C**) Lysates from Jurkat cells transfected for four days with siRNA against CYLD, USP34 (three individual sequences), or with control n.t. siRNA were analyzed by immunoblot as indicated. (**D and E**) NF-κB reporter luciferase assay (mean ± S.D. of triplicate experiments) of n.t.-, CYLD- or USP34-silenced Jurkat cells stimulated as in (A). RLU, Relative Light Units; Unst, unstimulated cells. (**F**) Cells as in (**C**) were stimulated with 20 ng.ml^-1^ PMA plus 300 ng.ml^-1^ ionomycin (P/I) for 1 and 2 hours. mRNA levels of NFKBIA (IκBα), IL-2, TNFα, and ACTIN were measured by RT-PCR. (**G**) Enzyme-Linked ImmunoSorbent Assay (ELISA) of IL-2 secreted in the supernatant of Jurkat treated as in (**C**) and stimulated with P/I. (**H**) NF-κB reporter luciferase assay of Jurkat cells transfected with the catalytic domain of USP34 (V5-tagged USP34-CD) or with a control empty vector (EV) and stimulated as indicated. Histograms represent mean ± S.D. of triplicate experiments. Inset blot shows USP34-CD expression when overexpressed in HEK293T cells.](1478-811X-11-25-1){#F1}

In addition to NF-κB, TCR ligation kindles various signaling pathways including Nuclear factor of activated T-cells (NFAT) and the Mitogen-activated protein kinase (MAPK) Extracellular signal-regulated kinases (ERK) \[[@B14]\]. Gene reporter assays showed only modest increase in NFAT activation in USP34-silenced when compared to control cells (Figure [2](#F2){ref-type="fig"}A). Furthermore, ERK phosphorylation occurred normally without USP34 (Figure [2](#F2){ref-type="fig"}B). Keeping with this, no overt change in the general pattern of tyrosine phosphorylation was observed upon TCR stimulation, further arguing against a general impairment of TCR signaling in the absence of USP34 (Figure [2](#F2){ref-type="fig"}C). We next investigated whether USP34 also curtailed NF-κB activity emanating from TCR-autonomous signaling triggers. To this end, USP34-silenced Jurkat cells were stimulated with the cytokine TNFα or with the genotoxic stress agent etoposide that functions via an unconventional ATM/PIASy/Sumoylated-NEMO axis \[[@B15]\]. Paralleling the situation with TCR, knocking down USP34 markedly increased NF-κB in cells treated with TNFα or etoposide (Figure [2](#F2){ref-type="fig"}D). Supporting previous studies with CYLD-deficient cells \[[@B10],[@B16]\], CYLD silencing in Jurkat cells also increased TNFα- and etoposide-mediated NF-κB activation (Additional file [4](#S4){ref-type="supplementary-material"}). Combined, these results indicate that USP34 shares some functional similarities with CYLD and selectively targets the NF-κB signaling pathway.

![**Knockdown of USP34 selectively potentiates NF-κB activation.** (**A**) NFAT reporter luciferase assay (mean ± S.D. of triplicate experiments) of Jurkat cells transfected with control non-targeting (n.t.) or USP34 siRNA and stimulated with 0, 0.1, 0.5, and 1 μg.ml^-1^ anti-CD3 and anti-CD28 antibodies (αCD3/28). RLU, Relative Light Units. (**B**) n.t.- and USP34-silenced Jurkat cells were stimulated with 20 ng.ml^-1^ PMA plus 300 ng.ml^-1^ ionomycin (P/I) for 0, 7.5, 15, 30 and 60 min. Cell extracts were prepared and analyzed by immunoblot as indicated. Molecular weight markers (*M.W.*) are shown. (**C**) Cells as in (**B**) were stimulated with 1 μg.ml^-1^ anti-CD3 and anti-CD28 antibodies. Cell extracts were prepared and general tyrosine phosphorylation pattern (P-Tyr) was evaluated by immunoblot. GAPDH served as a loading control. (**D**) NF-κB reporter luciferase assay of Jurkat cells transfected as in (**A**) and stimulated with 10 ng.ml^-1^ PMA plus 300 ng.ml^-1^ ionomycin (P/I), with 10 ng.ml^-1^ TNFα, or with 40 μM etoposide (VP16). Shown is the mean ± S.D. of triplicate experiments. Unst, unstimulated.](1478-811X-11-25-2){#F2}

To gain insights on the signaling basis for the exacerbated NF-κB activity in USP34-depleted cells, we first examined BCL10 and MALT1 ubiquitinylation status since it governs the strength of TCR-mediated NF-κB activation \[[@B4]-[@B6]\]. BCL10 ubiquitinylation, which can be assessed in fractions enriched with heavy membranes \[[@B17]\], remained unchanged without USP34 (Additional file [3](#S3){ref-type="supplementary-material"}A). Moreover, pull-down of CK1α to precipitate the CBM complex \[[@B7],[@B17]\], showed similar amounts of ubiquitinylated MALT1 bound in both control- and USP34-siRNA transfected cells (Additional file [3](#S3){ref-type="supplementary-material"}B). Keeping with this, BCL10 association to CARMA1 occurred normally without USP34 (Additional file [3](#S3){ref-type="supplementary-material"}C). We finally evaluated the impact of USP34 on the phosphorylation of IKK, which reflects its activation \[[@B8]\]. IKK phosphorylation was not exacerbated in those cells, and rather appeared slightly decreased (Figure [3](#F3){ref-type="fig"}A, and Additional file [3](#S3){ref-type="supplementary-material"}D). Although puzzling, this might result from a feedback loop triggered by enhanced NF-κB. We next assessed directly NF-κB DNA binding activity. Consistent with the gene reporter assays, more active NF-κB-DNA complexes were detected in nuclear extracts from TCR stimulated cells when USP34 was silenced (Figure [3](#F3){ref-type="fig"}B). Although no obvious difference in NF-κB subunit p65 translocation into the nucleus was detected, the degradation of the primary NF-κB inhibitor IκBα was more pronounced in cytosolic fractions from USP34-silenced cells when compared to control cells (Figure [3](#F3){ref-type="fig"}C). Accordingly, IκBα degradation was also prolonged or more dramatic in lysates from cells transfected with USP34 siRNA even on longer time points up to 3 hours (Figure [3](#F3){ref-type="fig"}D). Hence, our results suggest that USP34 likely functions downstream of the CBM-IKK nexus to enhance NF-κB activation.

![**Silencing of USP34 enhances IκBα degradation and NF-κB binding to DNA.** Jurkat cells were transfected with non-targeting- (n.t.) or USP34-targeting siRNA for 72-96 h. (**A**) Lysates from cells stimulated with 40 ng.ml^-1^ PMA plus 300 ng.ml^-1^ ionomycin (P/I) for 0, 10, 30 and 60 min were analyzed by immunoblot as indicated. *M.W.*, molecular weight markers. (**B**) NF-κB binding to DNA was assessed on nuclear extracts from cells stimulated as in (**A**) for the indicated time by non-radioactive electrophoretic mobility shift assays (EMSA) using biotin-labeled κB element DNA sequence. Note that DNA:p65 complexes were chased away with a cold probe, and were shifted when a p65 antibody was added. (**C**) Nuclear and cytoplasmic extracts from cells stimulated as in (**A**) were analyzed by immunoblot as indicated. GAPDH and PARP served as loading controls. (**D**) Lysates from cells stimulated as in (**A**) were assessed by immunoblot as indicated.](1478-811X-11-25-3){#F3}

Almost 100 DUBs were identified in the human genome and yet, only a few have been ascribed a function \[[@B11]\]. As for TCR signaling, the well studied A20 and CYLD thwart NF-κB at different levels \[[@B10]\]. CYLD targets and inhibits the ubiquitin-dependent IKKβ kinase TAK1 and therefore prevents aberrant lymphocyte activation \[[@B18],[@B19]\], while A20 dampens NF-κB activity by trimming K63-ubiquitin chains attached to MALT1 \[[@B20],[@B21]\]. Our study now unveils USP34 as an additional negative regulator of NF-κB in lymphocytes. How USP34 tempers NF-κB activity remains unclear. In contrast to CYLD and A20, which target apical signaling \[[@B18],[@B20]\], USP34 rather seems to function downstream of the IKK complex. Given that USP34 does not bind to the NF-κB core components (our unpublished results), we favor a model in which USP34 impacts on the activity of a cytosolic co-activator to ensure IκBα fine-tuning \[[@B22],[@B23]\]. Alternatively, USP34 might also intervene in other checkpoints to control NF-κB signal outcome and intensity such as post-translational modifications, nuclear shift, or DNA three-dimensional structure \[[@B22],[@B24],[@B25]\]. Nevertheless, our data illustrates how various layers of control cooperate to ensure the fine-tuning of NF-κB following engagement of the TCR.
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